← Back to Search

64Cu-LLP2A Imaging for Multiple Myeloma

Phase < 1

Recruiting

Led By Farrokh Dehdashti, M.D.

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult patients 18 years of age or older with clinically or pathologically defined MM in accordance with International Myeloma Working Group or as stated in office note / clinical assessment from treating physician.

Be older than 18 years old

Must not have

Unable to tolerate up to 90 min of PET/MR or PET/CT imaging per imaging session.

Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 hours after imaging

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new way to image multiple myeloma lesions using PET/MR. The hope is that this will help with early detection and choosing the best treatment.

Who is the study for?

This trial is for adults over 18 with multiple myeloma, including those newly diagnosed or previously treated who are starting new therapy. Participants must be able to consent and have no metal implants that interfere with PET/MR imaging. They should not be pregnant/nursing and have a GFR of at least 60 mg/mL/1.73 m^2 if receiving MRI contrast.

What is being tested?

The trial tests the use of a radioactive tracer called 64Cu-LLP2A in combination with PET/MR imaging to detect multiple myeloma lesions accurately. It aims to improve early disease detection and influence treatment choices by providing better molecular images of cancer.

What are the potential side effects?

Potential side effects may include reactions related to the injection of the tracer (like discomfort or bruising), allergic reactions, exposure to radiation from imaging, and any risks associated with biopsy procedures if performed.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older and have been diagnosed with multiple myeloma.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot stay still for up to 90 minutes for a scan.

Select...

I have not had any cancer other than non-melanoma skin cancer in the past 5 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 30 hours after imaging

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 30 hours after imaging

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 hours after imaging for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by average organ activity concentration of 64Cu-LLP2A

Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by image quality of 64Cu-LLP2A-PET/MR images

Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by lesion detection of 64Cu-LLP2A-PET/MR images

+2 more

Secondary study objectives

Comparision of tumor burden (SUVmax) of 64Cu-LLP2A to clinical measurement of tumor burden as measured by the plasma cell fraction within the bone marrow

Comparison of tumor burden (SUVmax) of 64Cu-LLP2A to clinical stage

Comparison of tumor burden (SUVmax) of 64Cu-LLP2A to clinical tumor measurement of tumor burden as measured by M-protein of myeloma

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort 2: Quantitative 64Cu-LLP2A ImagingExperimental Treatment7 Interventions

* 20 patients with MM will be recruited * Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed

Group II: Cohort 1: Pilot 64Cu-LLP2A ImagingExperimental Treatment7 Interventions

* 16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers) * All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry * 6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Urine sample

2011

N/A

~3370

PET/CT

2022

Completed Phase 3

~1300